Fig. 4

Chidamide enhances the antileukemia activity of adriamycin in leukemia-bearing mouse models. a Kasumi-1 tumor-bearing mice were treated with chidamide, adriamycin or both for 7 days. b shEZH2 Kasumi-1 tumor-bearing mice were treated with adriamycin for 7 days. c Tumor sizes. Tumor volume and weight were measured to assess leukemia burden in mouse models. d Expression of EZH2 and Smo/Gli-1 signaling were determined by histopathological and immunohistochemical examinations in leukemic tumor tissues. ^*P < 0.05; ^**P < 0.01; Ctrl control, Chi chidamide, shEZH2 EZH2 shRNA, ADM Adriamycin, Comb combination